Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-25
2007-12-25
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C568S945000, C530S300000, C548S567000
Reexamination Certificate
active
10901082
ABSTRACT:
Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).
REFERENCES:
patent: 5595756 (1997-01-01), Bally et al.
patent: 6166082 (2000-12-01), Kluender et al.
patent: WO 93/01824 (1993-02-01), None
Gura, T., “Systems for Identifying New Drugs are Often Faulty,” Science (1997), vol. 278, pp. 1041-1042.
Montagnier et al Activites Cytotoxique Et Antitumorale Des Beta-Nitrostyrenes, Chimie Therapeutique, Editions Dimeo, Arcueil, Fr, vol. 6, No. 3, 1971, pp. 186-191.
Okolotowicz et al, “Inactivation of Protein Farnesyltransferase by Active-Site-Targeted Dicarbonyl Compounds,” Arch. Pharm. Med. Chem.(2001), vol. 334, pp. 194-202.
Montagnier et al Activites Cytotoxique Et Antitumorale Des Beta-Nitrostyrenes, Chimie Therapeutique, Editions Dimeo, Arcueil, Fr, vol. 6, No. 3, 1971 ,pp. 186-191.
Bergo M.O., et al, “On the physiological importance of endoproteolysis of CAAX proteins: heart-specific RCE1 knockout mice develop a lethal cardiomyopathy,” J Biol Chem. Feb. 6, 2004;279(6):4729-36. Epub Nov. 18, 2003.
Montagnier et al Activites Cytotoxique Et Antitumorale Des Beta-Nitrostyrenes, Chimie Therapeutique, Editions Dimeo, Arcueil, Fr, vol. 6, No. 3, 1971, pp. 186-191, demonstrates a number of compounds used in vivo and in vitro.
http://en.wikipedia.org/wiki/In—vivo.
Organic Chemistry, 5th Ed. Morris & Boyd, p. 1205.
Montagnier et al Activites Cytotoxique Et Antitumorale Des Beta-Nitrostyrenes, Chimie Therapeutique, Editions Dimeo, Arcueil, Fr, vol. 6, No. 3, 1971, pp. 186-191., of record in IDS.
Kabalka and Varma,Organic Preparations and Procedures International1987, 19, 283-328.
The Merck Index Named Reactions, 182. Henry Reaction.
Nasr, et al.,Advances in Pharmacology and Chemotherapy1984, 20, 123-190.
Abstract of Cassels, et al.,Anales de la Asociacion Quimica Argentina1982, 70, 283-8.
Yuen and Cheng,J. Med. Chem. 1969, 12, 157-161.
Alston, et al.,Bioogranic Chemistry1985, 13, 375-403.
Alston, et al.,Acc. Chem. Res. 1983, 16, 418-424.
Fujii, Masayuki, “A Highly Chemoselective Reduction of Conjugated Nitro Olefins with Hantzsch Ester in the Presence of Silica Gel”, Bulletin of the Chemical Society of Japan,vol. 61(11), pp. 4029-4035 (1988).
Knight, John et al., “A New Acylative Cycoaddition Reaction”, Journal of the Chemical Society, Perkin Trans. I: Organic and Bio-Organic Chemistry (1972-1999), pp. 979-984 (1989).
Knight, John et al., “A New Acylative Cycloaddition Reaction”, Journal of the Chemical Society, Chemical Communications, pp. 189-190 (1987).
Knochel, Paul, et al., “Dehydration of Nitroaldols with Dicyclohexylcarbodiimide: Preparation of Nitroolefins under Mild Conditions” Synthesis, pp. 1017-1018 (1982).
Bezbarua, Maitreyee S., et al., “A Facile Procedure for the Conversion of Nitroolefins to Carbonyl Compounds using the Al-NiCl2*6H2O-THF System”, Chemistry Letters, pp. 325-326 (1999).
Saikia, Anil K., et al., The Zinc-Trifluoroacetic Acid Reaction in Organic Solvents: A Facile Procedure for the Conversion of Nitroolefins into Carbonyl Compounds under Mild Conditions, Journal of Chemical Research, Synopses, pp. 124-125 (1996).
Saikia, Anil K., et al., “An Improved Synethsis of Conjugated Nitroolefins”, Synthesis, pp. 685-686 (1994).
Montagnier, L. et al., “Activities Cytotoxique Et Antitumorale Des Beta-Nitrostytenes,” Chimie Therapeutique, Editions Dimeo, Arcueil, Fr. vol. 6, No. 3, 1971, pp. 186-191.
Okolotowicz, Karl J., et al., “Inactivation of Protein Farnesyltransferase by Active-Site-Targeted Dicarbonyl Compounds,” Arch. Pharm. Pharm. Med. Chem., vol. 334, 2001, pp. 194-202.
Cassels, et al.,Anales de la Asociacion Quimica Argentina1982, 70, 283-8.
Hartman Rosemarie F.
Houtchens Jason
Okolotowicz Karl J.
Rose Seth D.
Arizona Biomedical Research Commission
Gupta Anish
Heard Thomas S.
LandOfFree
Conjugated nitro alkene anticancer agents based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugated nitro alkene anticancer agents based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugated nitro alkene anticancer agents based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3869212